Biegon A, Essar N, Israeli M, Elizur A, Bruch S, Bar-Nathan A A
Weizman Institute of Science, Rehovot, Israel.
Psychopharmacology (Berl). 1990;102(1):73-5. doi: 10.1007/BF02245747.
Serotonin receptors of the 5-HT2 type were studied on platelet membranes from 15 patients suffering from major depression. Receptor binding and clinical state (assessed by the Hamilton and Beck rating scales) were examined in a drug free state upon admission and after 1 and 3 weeks of treatment with the antidepressant maprotiline (MPT). 5-HT2 receptor binding changed in correlation with changes in the clinical state of the patients as judged by the rating scales. Since most patients showed a clinical improvement, the patients as a group exhibited a significant decrease in binding concomitant with a drop in depression scores. However, in those patients in whom there was no clinical change or an increase in depression scores, 5-HT2 receptor binding did not change or increased, respectively, thus resulting in a significant correlation between clinical changes and changes in binding. These results support the use of 5-HT2 receptors on platelets in evaluating depression and its treatment.
对15例重度抑郁症患者血小板膜上的5-HT2型血清素受体进行了研究。在入院时以及使用抗抑郁药马普替林（MPT）治疗1周和3周后，在无药物状态下检查受体结合情况和临床状态（通过汉密尔顿和贝克评分量表评估）。根据评分量表判断，5-HT2受体结合情况与患者临床状态的变化相关。由于大多数患者临床症状改善，该组患者的结合显著减少，同时抑郁评分下降。然而，在那些临床症状无变化或抑郁评分增加的患者中，5-HT2受体结合分别未发生变化或增加，因此临床变化与结合变化之间存在显著相关性。这些结果支持利用血小板上的5-HT2受体来评估抑郁症及其治疗效果。
